v3.25.1
Segment Reporting - Summary of Revenue Significant Expenses and Net Loss for Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Segment Reporting Information [Line Items]      
Collaboration revenue $ 183 $ 532  
Research and development costs 4,876 18,238  
Restructuring and other related charges 885 0 $ 10,900
Total operating expenses 9,024 24,056  
Loss from operations (8,841) (23,524)  
Interest income 298 1,086  
Total other income 298 1,086  
Loss before income tax expense (8,543) (22,438)  
Income tax expense (4) (14)  
Net Income (Loss) (8,547) (22,452)  
Clinical Related Costs      
Segment Reporting Information [Line Items]      
Research and development costs 1,286 5,961  
Employee Related Costs      
Segment Reporting Information [Line Items]      
Research and development costs 3,075 9,475  
Product Development and Manufacturing Costs      
Segment Reporting Information [Line Items]      
Research and development costs 133 1,483  
Facilities, Support Costs and Depreciation      
Segment Reporting Information [Line Items]      
Research and development costs 2,672 4,065  
Professional, Consulting and Public Company Costs      
Segment Reporting Information [Line Items]      
Research and development costs $ 973 $ 3,072